Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – December 31, 2020
Message from the CEO
IBT is currently developing its lead drug candidate IBP-9414 to prevent necrotizing enterocolitis (NEC), and to improve so-called "feeding tolerance" in premature infants. IBP-9414 contains Lactobacillus reuteri as an active ingredient, which is a human bacterial strain found naturally in breast milk.
This message from the CEO is written during the continuing COVID-19 pandemic which now has been ongoing for one year. The pandemic appeared to be under control during the fall, however the outbreak of COVID worsened during November and December in many parts of the world. I have in previous quarterly reports described the impact of the pandemic on IBT. Simply put, our recruitment rate is affected, but the quality of data generated in the study is not. The bulk of the costs for conducting the study are incurred at the time of recruitment. This means that IBT’s liquidity is expected to be sufficient to complete the study even if the study is concluded at a later point in time.
Scientific articles published during the final quarter of 2020 stated that the birth rates of premature infants were lower than in previous years. The authors mention for example the fact of reduced shift-labor being performed along with improved diets, and also limited social contacts as possible factors affecting observations of reduced numbers of premature births. Regardless of the cause, we have received similar signals from our direct contact with neonatologists in our study that have also indicated reduced numbers in premature births. We expect the number of births to return to normal when the COVID pandemic decreases in intensity.
IBT’s study design includes infants with birthweights from 500 to 1 500 grams, however, thus far in the study we only included infants with birthweights from 750 to 1 000 grams, i.e. a range of 250 grams. IBT always applies the rule of caution, which is a regulatory key for us as the sole company worldwide with FDA approval of dosing premature infants with live bacteria. We have in addition to trial permits in the USA been granted approval for our study also in France, Hungary, Israel, Spain, and the UK, and in the fourth quarter also received approvals in Poland and Bulgaria. We currently have 68 active hospitals which are able to include patients compared to 62 in the previous quarterly report. It is against this background that we have chosen to open up for inclusion of patients under 750 grams only after reviewing the data from the initial 300 patients. We expect to have included 300 patients in the study within the month.
The fact that we during the initial phase of the study recruit patients in a narrow range of 250 grams, during an ongoing pandemic, has resulted in relatively few patient inclusions to date. IBT hopes that diminishing effects of the pandemic in combination with opening up the study to include infants born below 750 grams will significantly increase the recruitment rate during 2021.
We have during the fourth quarter aimed for a better understanding of the value of our second primary endpoint in the phase III-study, “sustained feeding tolerance”. After consultations with the FDA, an expert group has been established by IBT comprised of neonatologists, nurses, and patient organizations. Our goal with this expert group is to better understand as well as to demonstrate how malnutrition negatively affects premature infants both in the short and long term. These experts have already made clear that poor nutrition reduces growth of infants resulting in severe suffering in combination with high costs for healthcare payers. We seek to quantify the market value of improved “feeding tolerance” by our product IBP-9414 and I shall revisit the issue in due course.
We at IBT look forward to continuing our development work as our efforts can have great impact for all premature infants. Motivation will be even higher after the initial phase of this study, comprised of 300 patients, is concluded.
Stockholm, February 5, 2021
Chief Executive Officer
Financial overview for the period
|Fourth quarter (Oct-Dec) 2020||Reporting period (Jan-Dec) 2020|
Significant events during the fourth quarter (Oct-Dec) 2020
• The COVID-19 pandemic affects our development work, for example, activation of hospitals, which has not occurred at the desired rate. As of the date of this interim report, more than half of the planned hospitals have been activated. IBT's cash position is sufficient to carry out the ongoing Phase III study, even if recruitment in the study currently does not take place at the desired rate
Significant events during the reporting period (Jan-Dec) 2020
• IBT’s clinical study application was approved in Israel in January, in Poland in October and in Bulgaria in November
Significant events after the reporting period
• No significant events have occurred after the reporting period
|Selected financial data|
|Operating profit/loss||-26 702||-27 428||-71 918||-47 200|
|Result after tax, SEK||-26 726||-27 535||-72 007||-46 320|
|Total assets||450 318||518 273||450 318||518 273|
|Cash flow for the period (SEK)||-27 864||-8 546||-56 625||-51 301|
|Cash flow per share for the period (SEK)||-2.48||-0.76||-5.04||-4.57|
|Cash||423 438||495 188||423 438||495 188|
|Earnings per share before and after dilution (SEK)||-2.38||-2.45||-6.41||-4.13|
|Equity per share (SEK)||39.21||45.46||39.21||45.46|
|Equity ratio (%)||98%||98%||98%||98%|
About Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) is a pharmaceutical company with a product in clinical stage with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants.
IBT is currently developing the drug candidate IBP-9414, for the prevention of necrotizing enterocolitis (“NEC”) and improvement of feeding tolerance in premature infants. IBP-9414 contains the active substance Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. The product portfolio also includes another project, IBP-1016, for the treatment of gastroschisis, a severe and rare disease affecting infants. By developing these drugs, IBT has the potential to fulfill unmet needs for diseases where there are currently no prevention or treatment therapies available.
Infant Bacterial Therapeutics AB (“IBT”) is a public company domiciled in Stockholm. The company’s class B-shares shares are listed on Nasdaq Stockholm, Mid-cap (IBT B).
For additional information please contact
Staffan Strömberg, CEO
Daniel Mackey, CFO
Infant Bacterial Therapeutics AB
111 21 Stockholm
Phone: +46 70 670 1226
The information was submitted for publication on February 5, 2021 at 08:00 (CET).
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Prosafe SE: Safe Boreas to provide accommodation support at Buzzard27.2.2021 14:07:30 CET | Press release
Prosafe has signed a contract with CNOOC Petroleum Europe Limited for the charter of the Safe Boreas to provide gangway connected operations supporting the Buzzard platform complex in the UK sector of the North Sea. The firm duration of the contract commencing mid-April 2021 is 100 days with three 30-day options. The Safe Boreas will perform the gangway connected work scope using dynamic positioning, providing CNOOC Petroleum Europe Limited flexibility in operation. Total value of the contract excluding the option periods is approximately USD 8.5 million. Jesper Kragh Andresen, CEO of Prosafe says: "The Safe Boreas will strive to offer CNOOC the highest level of service. The Safe Boreas has operated extensively in the UKCS and will provide the safest working environment." Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to www.prosafe.com Stavanger
Mandalay Resources Corporation tillkännager resultatrapporten för fjärde kvartalet och helåret 202027.2.2021 08:53:04 CET | Pressemelding
TORONTO, Feb. 27, 2021 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation (”Mandalay” eller ”bolaget”) (TSX: MND, OTCQB: MNDJF) är glada över att tillkännage resultatrapporten för fjärde kvartalet och helåret som slutade den 31 december 2020. Bolagets konsoliderade finansiella resultat för året som slutade 31 december 2020, tillsammans med ledningens diskussion och analys (”MD&A”) för motsvarande period, finns tillgängliga under bolagets profil på www.sedar.com och på bolagets webbplats www.mandalayresources.com. Alla valutor i detta pressmeddelande avser US-dollar om inget annat är angivet. Höjdpunkter för fjärde kvartalet 2020: Intäkter på 45,3 miljoner USD;Justerad EBITDA på 25,3 miljoner USD, tredje högsta kvartalsresultatet i bolagets historia;Konsoliderat nettoresultat på 14,7 miljoner USD eller 0,16 USD per aktie; ochJusterat nettoresultat på 12,1 miljoner USD eller 0,13 USD per aktie. Höjdpunkter för helåret 2020: Intäkter på 179,0 miljoner USD, högsta helårsresultatet sedan 20
Annual financial report 202027.2.2021 08:00:00 CET | Press release
FINANCIERE DE TUBIZE SA/NV Allée de la Recherche 60, 1070 Brussels Contact: Anne Sophie Pijcke, directeur, firstname.lastname@example.org Annual financial report 2020 Regulated information 27 February 2021 The board of directors of Financière de Tubize has established the 2020 annual financial report. This report is available on the website www.financiere-tubize.be Dividend received from UCB: € 84,4 million (against € 82.4 million in 2019) Profit of € 81,0 million (against € 80.0 million in 2019)Decrease of outstanding debt from € 86.5 million at 31 December 2019 to € 33,5 million at 31 December 2020. If the general shareholders meeting of 30 April 2021 approves the 2020 annual accounts, including the proposed result appropriation, a dividend of € 0,68 will be payable as from 6th of May 2021 onwards at the offices, seats and branches of BNP Paribas Fortis, in exchange of coupon n° 16. Ex-dividend 4 May 2021 Record date 4 May 2021 Payment date 6 May 2021 In addition, the company Other Lo
Roche SARS-CoV-2 Rapid Antigen Test receives special approval for at-home patient self-testing using nasal swabs in Germany26.2.2021 18:30:00 CET | Press release
Special approval from German Federal Institute for Drugs and Medical Devices (BfArM) enables home use of a SARS-CoV-2 Rapid Antigen Test using a simple nasal swabThe test will be widely available in pharmacies across Germany Basel, 26 February 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced it has been granted special approval by the German Federal Institute for Drugs and Medical Devices (BfArM) to offer the SARS-CoV-2 Rapid Antigen Test using a simple nasal swab for patient self-testing in Germany. The test is a reliable rapid test for the qualitative detection of a specific SARS-CoV-2 antigen in nasal swab samples.This rapid antigen test collects the sample from the front area of the nose instead of the nasopharynx, resulting in a simplified and more comfortable sampling procedure. By following simple instructions, patients can perform the test at home with results ready after only 15 minutes. The test will be made available in pharmacies and requires no prescription. The G
Cargotec Corporation: Share Repurchase 26.2.202126.2.2021 17:40:00 CET | Press release
CARGOTEC CORPORATIONANNOUNCEMENT26.2.2021CARGOTEC CORPORATION: SHARE REPURCHASE 26.2.2021In the Helsinki Stock ExchangeTrade date26.2.2021Bourse tradeBuyShareCGCBVAmount40,362SharesAverage price/ share43.7441EURTotal cost1,765,599.36EURCargotec Corporation now holds a total of 300 531 sharesincluding the shares repurchased on 26.2.2021On behalf of Cargotec CorporationNordea Bank OyjJanne SarvikiviSami HuttunenFor further information, please contact:Mikko Puolakka, Executive Vice President and CFOtel. +358 20 777 4105Hanna-Maria Heikkinen, Vice President, Investor Relationstel. +358 20 777 4084www.cargotec.fi Attachment CGCBV_26.2_trades
Leasinvest Real Estate SCA sells the semi-industrial part of the Brixton Business Park in Zaventem26.2.2021 17:40:00 CET | Press release
Today the deed has been executed regarding the sale of the semi-industrial part of the Brixton Business Park in Zaventem, as already announced in the latest press release regarding the 2020 annual results. The buyer is an affiliate of Exeter Property Group. Knight Frank acted as the broker in this transaction. The Brixton Business Park comprises 5 semi-industrial buildings with a total area of 18,788 sqm. This divestment is fully in line with the strategy of Leasinvest, which is aimed at selling non-strategic properties and focusing on new sustainable projects. The current favorable market situation enabled a successful sale of this type of property. This divestment also has favorable financial effects: not only does the debt ratio now reduce to the targeted level of less than 55%, the realized capital gain on this transaction has also allowed Leasinvest to expedite the reimbursement of part of our derivatives portfolio, thus further reducing the average financing cost following the ea
Incap Corporation: THE BOARD OF DIRECTORS OF INCAP HAS RESOLVED ON PAYING A PART OF THE PURCHASE PRICE PAYABLE TO THE SELLERS OF AWS ELECTRONICS GROUP IN NEW SHARES OF INCAP CORPORATION26.2.2021 16:30:00 CET | Press release
INCAP CORPORATION STOCK EXCHANGE RELEASE 26 February 2021 at 5.30 p.m. (EET) THE PURCHASE OF AWS ELECTRONICS GROUP Incap Corporation (the “Company” or “Incap”) announced on 23 January 2020 that it has signed an agreement to acquire the entire share capital of AWS Electronics Group (“AWS”). The group has been included in Incap Group’s reporting as of 23 January 2020. The debt-free purchase price was 13.5 million pounds (then approximately EUR 15.9 million), and the additional purchase price amounted to EUR 0.6 million. The acquisition was financed with a loan of EUR 13 million and paid in cash, with the exception of an instalment of 0.6 million pounds to be paid in Incap shares. A PART OF THE PURCHASE PRICE The Board of Directors of the Company has on 26 February 2021 resolved, that the sellers of AWS will be paid an equivalent of 600,000 pounds in new shares of the Company in a directed share issue with payment (the “Share Issue”). The Share Issue will be consummated on 26 February 202